Swedish Orphan Biovitrum (Sobi)
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 3 |
Strategy profile
Based on 6 disclosed transactions, Swedish Orphan Biovitrum (Sobi) concentrates its licensing activity in Oncology, RareDisease, and Hematology. Swedish Orphan Biovitrum (Sobi) pays a 1.50x premium over market median. Their most common deal structure is Option, with an average disclosed value of $807M. Most recent activity: 2026.
Pipeline coverage & gaps
Swedish Orphan Biovitrum (Sobi) has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 2 | $75M | $580M |
| LicensePrimary | 2 | $165M | $368M |
| Acquisition | 1 | — | $1.7B |
| Collaboration | 1 | $250M | $1.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Lacutamab | Innate Pharma | cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides | phase_2 | $75M | $580M |
| 2026 | Lacutamab | Innate Pharma S.A. | cutaneous T-cell lymphoma (Sézary syndrome, mycosis fungoides) | phase_3 | $75M | $580M |
| 2025 | Aspaveli | Apellis Pharmaceuticals, Inc. | C3G and IC-MPGN | approved | $275M | $300M |
| 2023 | Vonjo (pacritinib) | CTI BioPharma | myelofibrosis | approved | — | $1.7B |
| 2022 | Zynlonta (loncastuximab tesirine) | ADC Therapeutics SA | relapsed/refractory diffuse large B-cell lymphoma (DLBCL) | approved | $55M | $435M |
| 2020 | pegcetacoplan (EMPAVELI / Aspaveli) | Apellis Pharmaceuticals | paroxysmal nocturnal hemoglobinuria (PNH) | phase_3 | $250M | $1.2B |
How this is computed
For each Swedish Orphan Biovitrum (Sobi) deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.691, clamped to [0.7, 1.5].